Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
about
Endothelin receptor antagonists for pulmonary arterial hypertensionEndothelin receptor antagonists for pulmonary arterial hypertensionSelective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue diseaseN-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control studyPrognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension.Life-threatening complications of adult-onset Still's disease.Systemic sclerosis-associated pulmonary arterial hypertensionSaudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary arterial hypertension associated with connective tissue diseasesMRTF-A steers an epigenetic complex to activate endothelin-induced pro-inflammatory transcription in vascular smooth muscle cellsBosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.Motivations of patients with pulmonary arterial hypertension to participate in randomized clinical trialsTreatment of pulmonary hypertension in patients with connective tissue disease and interstitial lung diseaseLung involvement in systemic sclerosis.Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases.Overview of current therapeutic approaches for pulmonary hypertension.Pulmonary arterial hypertension in connective tissue diseases.Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial HypertensionReview of bosentan in the management of pulmonary arterial hypertensionCharacterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.New therapeutic strategies in the management of systemic sclerosis.Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment.Clinical trials and basic research: defining mechanisms and improving treatment in connective tissue disease.Therapeutic targets in systemic sclerosis.Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trialsAssociation Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension.Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.Therapies for scleroderma-related pulmonary arterial hypertensionPulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.Pulmonary complications: one of the most challenging complications of systemic sclerosis.Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies.Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.Emerging drugs for pulmonary hypertension.Evidence-based management of rapidly progressing systemic sclerosis.Care of patients with scleroderma in the intensive care setting.Bosentan for the treatment of adult pulmonary hypertension.The initial 18 months of the first multi-disciplinary regional Pulmonary Arterial Hypertension Clinic in Australia.Treatment of pulmonary arterial hypertension in connective tissue disease.Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: a systematic review.
P2860
Q24200714-FDF7AD28-7D6C-4639-A86A-43498B8769EFQ24240009-BD38256B-CBAA-4FAA-A879-134215BFE9DAQ24681558-66CA49D6-0E21-44A4-BDFB-FA93280124DAQ30463476-77FEABDF-E2A9-4EE7-83DC-0C2AD94BB78CQ33398480-173481B0-ABA6-4E94-80F4-EC02B500CC79Q33412732-E58089E0-9192-4EBB-94E6-818060599A64Q33950086-1F025813-65CA-4ADB-ABF1-1ECC86C2833EQ33965825-2C948C05-A694-4DDD-B457-40206C5EDDC7Q34249545-DD52EF49-61C6-48B8-9E80-6B28246B5325Q34409802-B70564A5-571E-4496-B6B3-B9F766A9E227Q34420636-E71B0203-F0EF-4034-ABE4-3DD5E47D9148Q34425493-1D16DC6A-B07B-47BC-BFAD-C68152CF53D8Q34732817-97C2D372-ED67-4AB4-8315-F06FEDE055EAQ35161761-BF040FE1-D1EE-4B3E-BF97-1EDF95DBC9F6Q35412362-74765D53-C951-420F-BBD0-02CF9675EFEEQ36075852-86D78BB1-FF4F-4B41-A417-AE34BD6BA349Q36272410-A1B2C190-AB10-484A-BB9B-1A986F3AEAFCQ36596818-4FD3F8AB-8932-4DFB-82B8-440FA1725605Q36752821-35ECD4F9-3444-417C-851A-B0D2641C0FB8Q36765781-52502BA4-85DB-421E-ABF4-21F6E9CE3CBCQ36836706-0838209E-1F05-4209-BF14-C50269202070Q36839875-8342E331-72B5-487F-9783-28BDA8686136Q36927740-7F36A980-5BF2-42F6-9DD6-A337B43706FFQ36927761-7DFE0B84-134B-4FFE-95AA-55D8D20C7ED9Q36930712-031A87EC-7237-4C7A-B7B7-3511299B6EF9Q37069668-7E8AB57C-124F-492F-B8B1-3D89B0937C13Q37200751-5DAA48EF-DAEE-420B-9E54-2E7D7615FF9AQ37302470-0A1F1B17-F0E5-4C5D-84B9-4B21FA7E2340Q37364799-E8444F22-8E45-4DAB-944A-3C3CF6F0C408Q37504296-3A127304-2D24-4D3B-AFD0-C9186A5C2EFBQ37504310-F7DD951E-BA2C-4043-AD95-FA7829F219C0Q37538076-226D9184-B2E7-4547-942D-96691EB14974Q37616946-7C91598B-7803-49AE-B8EA-FF57AB48F510Q37679940-6386DF2D-B835-4A31-8120-31D622B9258AQ37763779-69C24029-2DAF-45EB-B531-EDBAA812BADCQ37764618-E13E1371-58EC-479A-BE8B-2D5554D7C3BFQ37822722-CCD40F0E-B1AC-47A2-9DB8-2E43F58E46A1Q37857895-6FAFAC9E-1452-4A1D-B167-83D79F20CD33Q38012530-2E8E9D74-EDF3-4200-B5AC-7C3290B20727Q38101137-69A1898E-8A5A-4004-A5AC-4AF0C140E21B
P2860
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Bosentan treatment for pulmona ...... d their open-label extensions.
@ast
Bosentan treatment for pulmona ...... d their open-label extensions.
@en
type
label
Bosentan treatment for pulmona ...... d their open-label extensions.
@ast
Bosentan treatment for pulmona ...... d their open-label extensions.
@en
prefLabel
Bosentan treatment for pulmona ...... d their open-label extensions.
@ast
Bosentan treatment for pulmona ...... d their open-label extensions.
@en
P2093
P2860
P356
P1476
Bosentan treatment for pulmona ...... nd their open-label extensions
@en
P2093
P2860
P304
P356
10.1136/ARD.2005.048967
P407
P50
P577
2006-06-22T00:00:00Z